Getting the Deal Through: Navigating Antitrust Scrutiny of Health System Deals and Beyond

Overview


According to a new report by the Health Care Cost Institute, nearly three-quarters of 112 metropolitan areas across 43 states have “highly concentrated” hospital markets—showing a rise of such areas from 67% in 2012 to 72% in 2016. And in today’s regulatory environment, this trend shows no sign of deceleration as health systems grapple with reimbursement, cost and other mission critical pressures.

This M&A activity is set against a backdrop of intensive antitrust scrutiny. The Federal Trade Commission (FTC) and often state attorneys general reviews can be challenging from a time and resource perspective. Join McDermott’s healthcare antitrust team for a webinar in which they’ll discuss and offer insight on what health systems and other industry participants can do to best position their deal for review. Topics include first-hand observations on various government practices, including:

  • Greater willingness to investigate discrete individual overlapping service lines and increasingly narrow geographic areas;
  • Growing reliance on econometric tools and economic analysis in their reviews;
  • Analytical approach toward markets where narrow and tiered networks are on the rise; and
  • Assessment of how local ACOs or CINs may factor into competitive effects analysis of a health system merger.

Dig Deeper

Paris, France / McDermott Event / October 18, 2022

European Healthcare & Life Sciences Symposium

London, United Kingdom / McDermott Event / September 29, 2022

HPE Europe 2022

Arlington, VA / National Vaccine Law Conference / September 15-16, 2022

National Vaccine Law Conference

Washington, DC / 340B Coalition Summer Conference / August 1-3, 2022

340B Coalition Summer Conference

Nashville, TN / HealthTrust / July 25-26, 2022

HealthTrust University Conference

Chicago, IL / McDermott Event / June 28, 2022

McDermott's Annual AHLA Meeting Reception 2022